Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.

Novo Nordisk remains the GLP-1 leader with over 65% market share. Read an in-depth BVO stock analysis and why we rate it as a ...

For comparison, Lilly's arch-rival in the weight-loss category, Novo Nordisk, is developing an oral formulation of ...

Q2 2025 Earnings Call Transcript August 6, 2025 Operator: Good day, and thank you for standing by. Welcome to the Q2 2025 ...

Novo Nordisk AS (NVO) reports significant sales and profit growth, driven by obesity care expansion and strategic ...

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...

Sales within Diabetes and Obesity care increased by 16% in Danish kroner to DKK 145.4 billion (18% at CER), mainly driven by Obesity care growth of 56% in Danish kroner to DKK 38.8 billion (58% at CER ...

Bagsværd, Denmark, 6 August 2025 - Financial report for the period 1 January 2025 to 30 June 2025 Operating profit increased ...

Novo Nordisk will hold its Q2 FY2025 earnings call on Wednesday, before the market opens. The company s having a terrible ...

Novo took the active ingredient of Ozempic, semaglutide, and rebranded it as Wegovy to be used specifically for weight loss.

Novo Nordisk is attractively valued after the sell-off, but near-term recovery requires patience. Read why I'm downgrading ...

Yesterday, we reported that Novo Nordisk (NYSE: NVO) stock crashed over 20% in premarket trading yesterday. The main culprit is the reduced sales forecast for the company’s flagship obesity drug ...